Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 51.11

-2.1%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Spekulatius who wrote (3276)	4/2/2001 11:06:16 AM
From: scaram(o)uche	Read Replies (4) of 52153

OK, let's pick some business plans that would/could be in trouble, given these worries/scenarios/whatever. TELK...... poorly-timed IPO didn't raise the funds anticipated or necessary to support plans. They're stating that they plan to take 289 forward alone. They don't have the cash to do such, but they're not going to run out soon. There's no near-term crunch. Phase II trials just initiated, research premium of about $85 million. What should they do? Should MLNM buy them (stock deal)? CRGN..... leverage...... a target discovery machine, trying to transition to a biologicals powerhouse. No pipeline to complement the massive stash of cash. What should they do? Who should they merge with? NPSP...... is the significant pile of cash sufficient? Are there any blockbusters in the broad pipe, something that says that the first merger/buyout/whateverbiowaandHarrywanttocallit will be sufficient? Should they just sit it out and pray? Other examples where answers might provide sector CEOs with a clue? Any answers to the questions asked?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next